{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-310472","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.490537+00:00","generated_at":"2026-05-16T14:02:21.169825+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"low","headline":"ORIC presents enozertinib Phase 1b update; no specific results in filing","bullets":["Company announced enozertinib (ORIC-114) program update on December 6, 2025.","Update covers data from Phase 1b trial; presentation attached as Exhibit 99.1.","No efficacy or safety figures included in the filing text itself.","Investors must refer to the separate presentation for detailed data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-310472","json":"https://secwatch.observer/filing/0001193125-25-310472.json","markdown":"https://secwatch.observer/filing/0001193125-25-310472.md","text":"https://secwatch.observer/filing/0001193125-25-310472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312525310472/0001193125-25-310472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312525310472/d46273d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:02:21.169825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}